Silibinin
Silibinin is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| skinceuticals silymarin cf acne treatment | C200263 | 2023-12-11 |
| skinceuticals silymarin cf acne treatment antioxidant | C200263 | 2024-06-24 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
110 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | 2 | 3 | — | 2 | 7 | 14 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | 1 | — | — | 3 | 5 | 9 |
| Fatty liver | D005234 | EFO_0003934 | — | 1 | 1 | — | 1 | 5 | 8 |
| Hepatitis | D006505 | — | K75.9 | 1 | 3 | 1 | 1 | — | 4 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | 1 | 1 | 3 |
| Fibrosis | D005355 | — | — | — | — | — | 1 | 2 | 3 |
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | — | — | — | 1 | 2 | 3 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | 1 | 1 | 1 | 3 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | — | 2 | 1 | 3 |
| Melanosis | D008548 | EFO_0003963 | L81.1 | — | 1 | — | 1 | 1 | 3 |
Show 7 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hepatitis c | D006526 | — | B19.2 | 3 | 8 | 3 | — | — | 10 |
| Chronic hepatitis c | D019698 | EFO_0004220 | B18.2 | 2 | 5 | 1 | — | — | 6 |
| Chemical and drug induced liver injury | D056486 | EFO_0004228 | — | 1 | 1 | 1 | — | 3 | 5 |
| Proteinuria | D011507 | — | R80 | — | 3 | 1 | — | — | 4 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | 1 | — | 3 | 4 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | — | 3 | 1 | — | — | 4 |
| Liver failure | D017093 | — | K72.9 | — | 1 | 1 | — | 2 | 4 |
| Drug-related side effects and adverse reactions | D064420 | — | T88.7 | — | 2 | 1 | — | — | 2 |
| Beta-thalassemia | D017086 | Orphanet_848 | D56.1 | 1 | 1 | 1 | — | — | 2 |
| Hepatitis b | D006509 | — | — | 1 | 1 | 1 | — | — | 2 |
Show 16 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Oxidative stress | D018384 | EFO_1001905 | — | 1 | 2 | — | — | 1 | 4 |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | — | 3 | — | — | — | 3 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 2 | 1 | — | — | — | 2 |
| Non-small-cell lung carcinoma | D002289 | — | — | — | 1 | — | — | 1 | 2 |
| Adenocarcinoma | D000230 | — | — | 1 | 2 | — | — | — | 2 |
| Recurrence | D012008 | — | — | — | 2 | — | — | — | 2 |
| Radiodermatitis | D011855 | — | L58 | 1 | 1 | — | — | 1 | 2 |
| Adenocarcinoma of lung | D000077192 | — | — | — | 1 | — | — | — | 1 |
| Hiv | D006678 | — | O98.7 | — | 1 | — | — | — | 1 |
| Alcoholic fatty liver | D005235 | — | K70.0 | — | 1 | — | — | — | 1 |
Show 17 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 2 | — | — | — | 3 | 5 |
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 1 | — | — | — | 2 | 3 |
| Hiv seronegativity | D018023 | — | — | 1 | — | — | — | — | 1 |
| Smoking | D012907 | EFO_0004318 | — | 1 | — | — | — | — | 1 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | — | 1 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Overweight | D050177 | — | E66.3 | — | — | — | — | 3 | 3 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | — | — | — | — | 2 | 2 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | — | — | — | — | 1 | 1 |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | — | — | 1 | 1 |
| Lactation disorders | D007775 | — | O92.4 | — | — | — | — | 1 | 1 |
| Lactation | D007774 | — | — | — | — | — | — | 1 | 1 |
| Human milk | D008895 | — | — | — | — | — | — | 1 | 1 |
| Wounds and injuries | D014947 | — | T14.8 | — | — | — | — | 1 | 1 |
| Irritable bowel syndrome | D043183 | EFO_0000555 | K58 | — | — | — | — | 1 | 1 |
| Hypercholesterolemia | D006937 | — | — | — | — | — | — | 1 | 1 |
Show 13 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Silibinin |
| INN | silibinin |
| Description | Silibinin is a flavonolignan isolated from milk thistle, Silybum marianum, that has been shown to exhibit antioxidant and antineoplastic activities. It has a role as an antioxidant, an antineoplastic agent, a hepatoprotective agent and a plant metabolite. It is a flavonolignan, a polyphenol, an aromatic ether, a benzodioxine and a secondary alpha-hydroxy ketone. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | COc1cc(C2Oc3cc(C4Oc5cc(O)cc(O)c5C(=O)C4O)ccc3OC2CO)ccc1O |
Identifiers
| PDB | — |
| CAS-ID | 22888-70-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1401508 |
| ChEBI ID | 125451 |
| PubChem CID | 31553 |
| DrugBank | — |
| UNII ID | 33X338MNE4 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 9,999 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
81 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use